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 INTRODUCTION 
Chronic obstructive pulmonary disease, a disorder of expiratory 
airflow has been projected to be the 3
rd 
leading cause of mortality and 
5
th 
cause for disability as measured by DALY in 2020 by the Global 
burden of Disease study. It is one of the few diseases whose 
morbidity and mortality are increasing at an alarming rate day by day 
and imposing a heavy economic burden on the countries particularly 
the developing countries like others. Reasons for this troubling 
situation include the reduction in other cause mortality increasing the 
longeivity of the population, increasing tobacco use & increasing 
environmental pollution. The situation is so alarming that the disease 
has achieved epidemic proportions. Many advances have been made 
recently in the diagnosis and management of this disease but the hard 
fact is that the disease is one of gradual progression, increasing 
morbidity and incurable and the better way to handle this by 
prevention by healthy life style, very importantly avoiding tobacco 
use. 
Chronic obstructive pulmonary disease is a disorder of 
pulmonary inflammation and in contrary to yester years belief that it 
is confined only to the respiratory system, studies over the recent 
 9 
years have thrown much light on the  systemic component of the 
disease largely due to oxidant stress and which in addition to the lung 
manifestations has been attributed to the extra pulmonary 
manifestations such as coronary artery disease which is the leading 
cause of mortality in these patients, osteoporosis, development of 
diabetes, loss of muscle mass – these impose health burden on these 
patients with already deranged lung function. As the pathophysiology 
of the varied manifestations of the disease are being unraveled 
everyday recent studies are on to find a unified marker which could 
reliably predict the entire disease manifestations, disease course,  
which could help in making treatment plan and also studies are on to 
find a way of halting the unrelenting inflammation and disease 
progression. Among the various markers being tested, one such is 
highly sensitive C-Reactive Protein. 
In the present study the baseline characteristics of our patients 
are analysed and to possibly see whether highly sensitive C-Reactive 
Protein correlates with the disease severity. 
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AIMS AND OBJECTIVES 
 
The present study was done 
1. To study the clinical profile of COPD patients with respect to their 
baseline characteristics – age, sex, occupation, symptoms, signs, X-
ray, ECG, ECHO, BMI, pack years of smoking 
2. To categorize the patients based on spirometry into different stages 
and to study the distribution of the baseline characteristics in each 
stage 
3. To determine the value of hs-CRP in these patients and to correlate it 
with the various stages, smoking pack years, FEV1 and other 
variables and its significance 
4. To study other markers of inflammation such as ESR, serum albumin  
and their variation with stages and lung function. 
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REVIEW OF LITERATURE 
DEFINITION 
4 
COPD is defined as “a disease state characterized by airflow 
limitation that is not fully reversible” 25,31 It includes 
I. EMPHYSEMA
4 
Emphysema is defined as “destruction and enlargement of the 
lung alveoli” 
II. CHRONIC BRONCHITIS
4 
Chronic bronchitis is clinically defined with chronic cough and 
phlegm production.  
III. Small Airway disease  
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GOLD criteria for COPD severity
4 
GOLD 
stage 
Severity  Symptoms  Spirometry  
0 At risk Chronic cough, 
sputum production 
Normal 
I Mild  With or without 
chronic cough or 
sputum production 
FEV1/FVC < 
0.7 and FEV1 ≥ 
80% predicted 
II Moderate  With or without 
chronic cough or 
sputum production 
FEV1/FVC < 0 
.7 and 50% ≤ 
FEV1% < 80% 
predicted 
III Severe  With or without 
chronic cough or 
sputum production 
FEV1/FVC < 
0.7 and 30% ≤ 
FEV1% < 50% 
predicted 
IV Very severe With or without 
chronic cough or 
sputum production 
FEV1/FVC < 
0.7 and FEV1 < 
30% or FEV1% 
<50% predicted 
with respiratory 
failure or signs 
of right heart 
failure 
 
EPIDEMIOLOGY
 29,30 
COPD is expected to be the 3
rd
 most common cause of mortality 
and the 5
th
 for loss of DALY worldwide according to Global Burden 
of Disease Study.
 46 
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PREVALENCE IN INDIA 
The exact prevalence in our country could not be ascertained 
with certainty because of misdiagnosis, under assessment, lack of 
extensive studies, poor statistical information. The prevalence rate 
have been variably reported from 2-22% in males and 1.2-19% in 
females. Recently ICMR has undertook the INSEARCH study in four 
cities and reported prevalence of 5% in males and 3.2% in females in 
those more than 35 years of age. The total population affected by the 
disease has increased to 14.84 million in 2011 from 6.45 million in 
1971. In India the sex ratio and the smoker to non smoker ratio  are 
not as high when compared to western statistics. This disparity is 
because of biomass fuel combustion which is an important risk factor 
in women more so in the villages. Data on mortality statistics are 
limited; 7% mortality have been attributed to chronic respiratory 
illness.
29,30 
RISK FACTORS 
SMOKING 
4,5,6,11,25,30,31,35 
Cigarette smoking by far is the major cause for COPD with 
proven cause-response relationship with approximately half of 
 14 
smokers developing the disease. The effect of smoking on declining 
lung function have been proved in many studies. But still not all 
smokers develop the disease and even among those who smoke there 
is variation in response to the duration of smoking which suggests 
that other factors particularly genetic and environmental modulate the 
effect of smoking in these patients. 
AIRWAY RESPONSIVENESS 
4,11 
Though the concept of airway hyperresponsiveness have been 
proved beyond doubt in bronchial asthma, in COPD there are 
conflicting reports as to whether it contributes to the development of 
airflow obstruction  with recent studies supporting the hypothesis. 
RESPIRATORY INFECTIONS 
4,30 
Infections associated with risk 
a. Previous H/O tuberculosis even when adequately treated with ATT 
b. Childhood respiratory infections 43 
c. Inadequately treated bronchial asthma     
INDOOR AIR POLLUTION 
4,29,30 
Though in developed countries smoking is the major risk factor, 
in developing countries like ours causes other than smoking 
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contribute to 1/3  to ½ of all cases. Among them chronic exposure to 
sulfur dioxide, carbon monoxide, nitric oxide, HCHO and others 
released from biomass fuel combustion
38
 is the important risk factor 
particularly in female patients. 
OCCUPATIONAL DUSTS 
4,30 
Several occupations are met with chronic exposure to 
occupational dust/gas but the impact of these agents in the 
development of the disease is much less significant than cigarette use. 
INCREASING AGE : 
30
  
Physiological decrease in pulmonary function could also lead to 
the disease. 
LOW SOCIO-ECONOMIC STATUS
 29,30 
GENETICS 
4,5,6,10,11,30 
The considerable variation in smokers developing the disease 
could possibly due to various genetic derangements. As of now, the 
only proven genetic defect causing the disease is α1-antitrypsin 
deficiency which is due to alteration in SERPINA1 locus encoding 
the enzyme. 
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Allele α 1 AT 
M Normal 
S Slightly reduced 
Z Markedly reduced 
Null Absent 
  
Pi
Z 
 - most common form. 
Treatment for this subset of patients is available as α1-AT 
augmentation therapy as weekly intravenous administration. 
Apart from α1-AT deficiency, other genetic factors have also 
been hypothesized to contribute to the risk factor pool and research on 
several other genes are underway.
4 
PATHOPHYSIOLOGY
 
AIRFLOW LIMITATION
 4,11,30 
Airflow limitation due to decreased airway caliber and 
increased airway resistance, impaired elastic lung recoil during 
expiration manifested in spirometry as reduction in the ratio of Forced 
Expiratory Volume1/Forced Vital Capacity < 0.7 and reduced post 
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bronchodilator FEV1% predicted value is a cardinal feature for the 
disease diagnosis and dividing into stages. 
HYPER INFLATION 
4,11 
In these patients there is hyper inflation as shown by increased 
RV and increased ratio of RV/TLC and later increase in TLC. 
Mechanism
 30 
The principal mechanism of airflow during expiration from the 
small airways and alveoli is driven by the inward elastic recoil 
pressure of the lung which also counteracts thoracic wall outward 
pressure. At the end of tidal expiration both these balance each other 
resulting in particular amount of air remaining in the lungs named as 
FRC (functional residual capacity). In these patients due to the 
destruction of lung parenchyma, the inward pressures are low and it 
comes into equilibrium with the outward pressure at increased 
volumes of FRC resulting in hyperinflation. This state of 
hyperinflation also causes flattening of diaphragm resulting in 
functional diaphragmatic paralysis.  
 
 
 18 
GAS EXCHANGE 
4 
Hypercapnea and hypoxia results from deranged gas exchange 
due to the reduction in surface area caused by destruction of the 
respiratory units. The chronic hypercapnic state decreases the 
chemoreceptor sensitivity and hence the respiratory stimulus in these 
patients is hypoxia stimulating the peripheral chemoreceptors.
30 
V/Q MISMATCH 
4 
It is due to the inhomogeneous disease distribution in the lungs 
and airways 
PATHOGENESIS 
ELASTASE-ANTI ELASTASE HYPOTHESIS 
4,10,11 
α 1 – AT DEFICIENCY: 
Neutrophils in the alveoli are stimulated by various triggers 
which get activated and recruited and release their granules which 
have elastase, proteinases, cathepsins & MMP and also releases ROS 
which inhibit α1 anti trypsin. In patients with the enzyme deficiency, 
these elastases cause destruction of the air spaces. 
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Smoking  
In smokers both neutrophils and macrophages are increased in 
alveoli. Neutrophils upon activation releases a number of proteases 
mentioned above and activated macrophages release a variety of 
cytokines, chemokines, ROS and a variety of matrix 
metalloproteinases which are not inhibited by α1 AT rather these 
enzymatically degrade α1 AT and thus enhancing pulmonary 
destruction several fold.
10
 CD8 lymphocytes enhance apoptosis of 
alveoli and CD4 cells trigger autoimmunity against native lung 
tissue.
30 
OXIDANT STRESS 
The normal lung contains rich anti-oxidants such as  glutathione 
to handle the oxidant stress. Smoking by way of its contents and also 
by activating inflammatory cells which release free radicals tilt the 
balance towards oxidant stress which inactivates anti-proteases 
causing lung destruction in patients even with normal α1 AT. Oxidant 
stress also results in loss of surfactant, ECM apoptosis, reduction in 
elastin synthesis.
10 
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CLINICAL PRESNTATION 
HISTORY 
SYMPTOMS 
4,5,6,11 
i. Chronic cough 
ii. Expectoration 
iii. Dyspnoea on exertion – insidious in onset and gradually progressive 
over time. Sudden worsening of dyspnoea is due to either an 
exacerbation or other complications. 
iv. Wheeze 
v. Loss of weight – in severe disease. (other causes to be ruled out 
before attributing it to the disease per se.) 
SIGNS : 
4,5,6
    
The physical examination may be completely normal in patients in the 
beginning stages till there is significant deterioration in pulmonary 
function. 
GENERAL EXAMINATION 
a. Stigmata of smoking – nicotine stains, etc. 
b. Cyanosis may be present 
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c. Clubbing is not a sign of the disease per se and if present a prompt 
search for other conditions such as lung Ca has to be made. 
d. Pedal edema, ascites, elevated JVP – due to pulmonary hypertension 
& cor pulmonale. 
e. SPO2 – patients may have hypoxemia. 
RESPIRATORY SYSTEM EXAMINATION 
a. Patients with severe disease have accessory muscles of respiration 
acting with the patient assuming “tripod” position to enhance the 
synergistic action of these muscles 
4
 
b. Hoover’s sign 4 
c. Signs of hyperinflation – Barrel shaped chest, hyper resonance on 
percussion.
4
 
d. On auscultation patient may have prolonged expiratory phase, 
diminished intensity of breath sounds, expiratory wheeze.
4,6
 
e. Signs of pulmonary hypertension and cor pulmonale – Loud P2 may 
not be present due to hyperinflation, Tricuspid regurgitation murmur 
can be present.
4
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DIFFERENTIAL DIAGNOSIS 
5 
a. Bronchial asthma – distinguished by near total post bronchodilator 
FEV1 reversibility. 
b. Bronchiectasis – differentiated by symptoms like hemoptysis, 
presence of clubbing & radiography. 
c. Cystic fibrosis – history since childhood, recurrent infections, 
presence of other features such as cirrhosis. 
d. Broncho pulmonary mycosis. 
e. Central airway obstruction such as tumours, stenosis or 
developmental anamoly – differentiated by history and PFT using 
flow-volume loops. 
COMPLICATIONS 
5,30 
i. Recurrent lung/airway infection 
ii. PTE 
iii. Cor pulmonale and pulmonary hypertension 
iv. Bronchogenic carcinoma 
v. Pneumothorax especially in those with emphysema 
vi. Cardiovascular effects – CAD, arrhythmias. 
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RADIOGRAPHY
  
X-RAY CHEST 
4,5 
i. Chronic bronchitis – Increased bronchovascular markings 
ii. Emphysema –    Hyper inflated lung fields 
                                     Diaphragm flattening 
                                     Decreased peripheral vascular markings 
                                     Bulla 
iii. Pulmonary hypertension – enlarged main & right descending 
pulmonary artery 
iv. To look for co morbidities and complications like malignancy, 
pneumothorax, etc. 
COMPUTED TOMOGRAPHY 
4 
a. Not routinely done for diagnostic purposes 
b. To assess patients fit for surgical  management. 
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LABORATORY TESTS 
PFT : 
4,5,6,31 
a. FEV1/FVC < 0.70 
b. TLC, FRC, RV may increase often more than normal with 
disease progression. 
  Apart from diagnostic utility, FEV1 is also used to monitor 
treatment response and worsening FEV1 is a poor prognostic factor. 
ABG : 
4,6 
a. Normal in early stages 
b. To determine the degree of hypoxemia and the acid base status and to 
differentiate between acute exacerbations and chronic respiratory 
failure. 
c. Yearly assessment is recommended. 
TREATMENT  
STABLE PATIENTS 
Survival improving strategies 
4,5,6,11,30,35 
1. Smoking cessation 
2. Oxygen 
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3. Lung volume reduction surgery 
Other management strategies are to the relief of symptoms, 
improving the quality of life and to reduce exacerbations. 
4 
DRUGS 
BRONCHODILATORS 
4,5,6,11,30 
These drugs are the mainstay of management in that they 
provide symptom relief and enhances the well being of patient but do 
not prevent the decline in FEV1. 
Inhaled β2 agonists :  
i) short acting β2  : used in all stages of the disease ‘on demand’ basis 
to provide immediate relief from dyspnoea and not to be used on a 
routine basis. 
Drugs used are salbutamol and levosalbutamol. 
30 
ii) long acting  : used on a scheduled basis as maintenance therapy to 
provide sustained relief. 
Drugs commonly used are formoterol, salmeterol. 
Side effects : Tachycardia, tremor, decrease in serum K
+. 30 
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Inhaled Anti-cholinergics : 
i) short acting : For symptom relief similar to short acting beta 2 
agonists but devoid of their sympathetic side effects and also has 
prolonged action compared to them. 
Drug used ipratropium 
ii) long acting : for maintenance therapy 
Side effects : dryness of mouth, Primary angle closure glaucoma is an 
absolute contra indication, symptoms of BPH may aggravate. 
COMBINATION THERAPY 
30 
As the disease worsens, combination therapy with Long acting 
sympathetic and anticholinergic provides maximum symptom benefit 
by synergistic mechanisms rather than single drug alone. 
CORTICOSTEROIDS 
INHALED :  
ICS are not to be used as a single agent in management of these 
patients but used in combination with other inhaled bronchodilators.
5 
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Indication :
 30 
i. Stage III disease 
ii. ≥2 exacerbations / year 
Side effects : 
30 
1. oral candidiasis – prevented by mouth gargling after each use or by 
spacer 
2. hoarseness of voice 
SYSTEMIC STEROIDS 
4,5,6,30 
Oral steroids are not used in the regular treatment of stable 
patients because the adverse effects outweigh the benefits but they are 
an important part of acute exacerbation management. 
METHYL XANTHINES 
5,6,30 
Sustained release theophylline is commonly used in patients 
who do not have adequate symptom relief with inhalational therapy 
because of its effects on diaphragm function, reducing airway 
resistance and decreasing inflammation. 
Side effects :
 6,30 
These drugs have a narrow therapeutic window and patients’ 
supervision is essential. 
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 CVS  : increase in heart rate, arrhythmia. 
 CNS  : tremor, decreases seizure threshold, insomnia. 
 GIT  : gastritis, nausea. 
ANTIBIOTICS - No role in stable patients. 
5,30 
NON PHARMACOLOGICAL MEASURES 
OXYGEN 
4,5,6,30 
Oxygen therapy by various methods undoubtedly prolongs 
survival and also provides symptom relief. 
Indications
 6,42 
 Arterial partial pressure of O2 ≤ 55 mm Hg or oxygen 
saturation by pulse oximetry ≤ 88% 
 Arterial partial pressure of O2 < 60 mm Hg and oxygen 
saturation < 90% in the presence of pulmonary 
hypertension, Hct > 55% or cor pulmonale. 
VACCINATIONS 
6,30,34 
For all stages of the disease yearly influenza vaccine and 
pneumococcal vaccine (zero dose and a booster after 5 years ). 
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PULMONARY REHABILITATION 
4,5,6,30 
It is a multi system modality including respiratory exercises, 
adequate nutrition, psychological support that improves exercise 
tolerance, improves dyspnoea and quality of life indicated in patients 
failing optimal medical therapy and also for severe disease. 
SURGICAL MANAGEMENT 
I. LUNG TRANSPLANTATION 
4,5,6 
a. Done either as one lung or sequential double lung transplant 
b. Requirements include severe disease inspite of optimal medical 
management, absence of other organ system dysfunction, poor quality 
of life. 
c. PHT and the region of lung involved are not contra indications. 
II. LUNG VOLUME REDUCTION SURGERY 
4,5,6 
Patients with upper lobe emphysema and severely compromised 
exercise tolerance are ideal candidates. Presence of PHT/cor 
pulmonale are contra indications. 
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III. BULLECTOMY
 5 
EXACERBATIONS OF COPD 
PRECIPITATING CAUSES 
4,30 
I. Infections 
i. Viral infections 
ii. Bacterial infections 
a. Pneumococcus 
b. Hemophilus influenza 
c. Moraxella catarrhalis 
d. Pseudomonas in special risk groups 
II. Environmental  
i. Pollution 
ii. Exposure to toxic gases 
iii. Climate changes 
SYMPTOMS 
4,30 
i. Increase in cough 
ii. Worsening dyspnoea 
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iii. Increased sputum with purulence 
iv. Worsening general condition 
 
Complete physical examination is mandatory to assess the 
severity of the exacerbation. Investigations done include X ray chest 
to detect the presence of pneumothorax, consolidation, ECG to detect 
rhythm disturbances- most common being MAT,  ABG to detect 
respiratory failure. The decision as to whether the patient has to be 
treated at home or hospital or ICU is based on the severity, patient’s 
general health status, supportive care, presence of other co 
morbidities like CAD, DM, neurological status, ABG measurements 
and the need for assisted ventilation.
 4,6,30 
DRUGS 
BRONCHODILATORS 
Short acting beta agonists are used as the primary treatment  for 
an exacerbation, alone or in addition with an anti cholinergic 
delivered through nebulisation or inhalation if patient can perform.
6
 If 
patient is already taking methyl xanthines it should not be stopped as 
it may cause deterioration but monitoring of drug levels is mandatory. 
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In theophylline naïve patients it should not be prescribed during an 
exacerbation. 
5,6 
GLUCOCORTICOIDS 
Systemic steroids via oral or parenteral if patient cannot take 
medication orally for short course is an important cornerstone in 
management of exacerbation because they decrease hospital stay, 
improves lung function and decreases the probability of subsequent 
relapse. 
4,6,30 
ANTIBIOTICS 
They are chosen based on the sensivity pattern, the likely 
organism and availability and is particularly useful in patients with 
purulent sputum production and in those requiring assisted 
ventilation.
 4,6 
SUPPLEMENTAL OXYGEN  
To maintain SaO2 ≥ 90%.
6
 Oxygen should not be withheld for 
fear of respiratory depression due to removal of hypercarbic stimulus 
because it is essential to prevent tissue hypoxemia but care should be 
exercised in monitoring the patient. 
5 
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ASSISTED VENTILATION 
Non invasive ventilation indicated in patients with respiratory 
failure has shown to decrease mortality, decrease hospital stay, the 
need for invasive ventilation and lesser risk of hospital acquired 
infections. Invasive ventilation is indicted when NIV fails or patient 
has contra indications to NIV or severe acidosis or hypercapnea or  
the presence of co-morbidities.
4,5,6,30 
PULMONARY HYPERTENSION IN COPD : 
Mild PHT to some extent develops in most of the patients with 
advanced disease and rarely severe pulmonary HT in few.
 7,37 
CAUSES 
7 
1. Pulmonary vasoconstriction caused by alveolar hypoxia,37 acidosis, 
hypercapnia. 
2. Increased lung volume causing compression  of Pulmonary vessels 
3. In patients with emphysema due to terminal air space destruction 
there is a decrease in the small vessels in areas of destroyed lung 
tissue. 
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Pulmonary artery pressure increases by approximately 20 mm 
Hg for every acute exacerbation and this can end up in pulmonary 
hypertension on repeated occurrence. 
9,30 
MECHANISM OF PULMONARY HYPERTENSION BY 
HYPOXIA:
 7 
1. Vascular intima thickening 
2. Distal vessels muscularisation 
3. Hypertrophy of the vascula media of proximal vessels 
4. Alveolar hypoxia in order to maintain V/Q and PaO2 is a potent 
vasoconstrictor in pulmonary circulation. 
TREATMENT 
7,44 
A. Pulmonary vasodilators produce worsening of V/Q mismatch because 
it is not the level of pulmonary hypertension but the degree of 
hypoxia which causes the clinical symptoms and that these drugs 
further worsen the situation. 
B. Only proven  treatment of use is O2 which decreases both morbidity 
and mortality 
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C. To maintain the Hb in upper limit of normal because low Hb is not 
tolerated in these patients due to hypoxemia. 
Nocturnal or ambulatory SaO2 can guide in optimal O2 concentration.  
COR PULMONALE ( RIGHT HEART FAILURE ) : 
44 
It can occur either acutely during exacerbations or chronically 
due to disease progression and worsening gas exchange resulting in 
irreversible vascular remodeling. 
DIAGNOSIS 
i) Echocardiogram  
To detect the presence of right ventricular enlargement but the 
procedure is difficult due to hyperinflated lungs and rotation of the 
heart.
8
 It can be supplemented by ABG-showing PaO2 < 50 mm Hg 
and PCo2  > 50  mm Hg.
44 
ii) Electrocardiogram
 44 
Routine criteria to detect RVH cannot diagnose RVH in these 
patients due to  
a. rotation of the heart 
 36 
b. Hyper inflation causing increased distance between the skin 
and cardiac surface. 
c. It is more of  RV dilatation rather than hypertrophy. 
iii) Cardiac catheterization – gold standard investigation. 44 
MANAGEMENT 
44 
1) Acute cor pulmonale 
    i) treatment of the precipitating cause 
    ii) supplemental O2 to maintain adequate oxygenation. 
2) Chronic cor pulmonale 
    i) cautious use of digoxin and diuretics for the fear of precipitating 
life threatening rhythm disturbances in the presence of hypoxia and 
acidosis. 
    ii) Oxygen. 
SPIROMETRY IN COPD 
 
The investigation to confirm or refute a diagnosis of the disease 
is spirometric evaluation as suggested by GOLD. According to them a 
post bronchodilator Forced expiratory volume 1/ Forced Vital 
Capacity < 70%  is used for diagnosis and the previous concept of 
 37 
absence of post bronchodilator reversibility has been abandoned. 
Spirometry has its own limitations and hence a combination of 
clinical symptomatology and spirometry improves the diagnostic 
accuracy. 
30 
USES 
30 
1. Diagnosis 
2. Grading of severity 
In these patients the rate of decrease in Forced expiratory 
volume1 per year is about 75-100 ml in sharp contrast to normal 
persons’ 30 ml/year. 
3. Lung “age” assessment 
By comparing patient’s FEV1( lung age) to the predicted FEV1 
of his age matched control. It could be used to encourage smokers to 
quit smoking. 
4. Detection of Upper airway obstruction 
5. Pre-Operative evaluation 
       These patients have a higher chance of developing post-op 
pulmonary complications. 
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i) Thoracic surgery 
          Predicted Post operative FEV1 is calculated by applying “rule 
of 5” in which 1/5th function is contributed by each lobe and the PPO 
value is calculated by subtracting the lobe to be removed. A PPO 
FEV1 < 40% predicted is a contra indication to surgery. 
ii) Non thoracic surgery  
Factors predicting post-operative complications are 
a. FEV1/FVC <50% 
b. Maximum voluntary ventilation < 50% 
c. FEV1 or Diffusing capacity < 20% predicted 
d. High partial pressure of carbon dioxide 
e. Short distance of surgical site from the chest 
SYSTEMIC INFLAMMATION 
30 
It has been recognized from the experiences in past decades that 
inflammation is no longer confined to lungs in COPD and that GOLD 
definition of the disease at present includes  “some significant extra 
pulmonary effects that may contribute to the severity in individual 
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patients” and hence the disease could be renamed as “chronic 
systemic inflammatory syndrome”. 
MARKERS OF SYSTEMIC INFLAMMATION IN COPD 
30 
1. hsCRP 
2. Fibrinogen 
3. Ferritin 
4. White blood cell count 
5. ROS 
6. Interleukins 
7. TGF β1 
8. TNF α receptor polymorphism 
These markers are present even in mild forms of the disease and 
their levels increase with increasing disease severity. 
HYPOTHESIS 
30 
1. Probable inflammation spreading over from lungs to other systems. 
2. A proinflammatory phenotype in which systemic inflammation 
happens independent of lung component. 
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TRIGGERS 
30 
1. Smoking an important risk factor for the disease per se by way of 
causing oxidative stress & endothelial function derangement  
2. Hypoxia of severe disease enhances HIF-1 expression.HIF-1 
upregulates genes involved in inflammation, vascular remodeling & 
new vessel formation. TNF-α levels have been shown to be in relation 
with hypoxemia severity and that the enhanced survival of patients on 
LTOT might be due to the fact that oxygen decreases inflammation. 
3. Increased leptin levels and its receptors  
4. Auto-immune process 
5. Oxidative stress of the disease accelerates telomere shortening and 
causes “ageing” of lungs and other systems. 
CONSEQUENCES 
30 
Consequences of the systemic inflammatory process are the non 
pulmonary morbidities that have been shown to have immediate 
cause-effect relationship across studies consistently and also have 
been proven that their association is not just by chance. 
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1.  CARDIO VASCULAR SYSTEM : 
30 
i) Coronary Artery Disease: 
These patients have a 3-fold greater risk of developing CAD 
and that the mortality rates in these patients due to CAD  are 
comparable to those due to worsening of the disease per se. Cardiac 
injury biomarkers have been shown to be increased in studies during 
acute exacerbations when the level of systemic inflammation is high. 
ii) Cardiac failure: 
Cardiac failure is precipitated by end diastolic pressure changes 
induced by pressure variation caused by hyper inflation which 
interferes with ventricular remodeling. Cardiac failure and air flow 
limitation is a vicious cycle – one perpetuating the other in that 
airflow resistance is worsened by the electrolyte changes, mucosal 
congestion & decreased lung compliance in heart failure. 
iii) Arrythmias: 
The common rhythm disturbances include 
a. Mutifocal Atrial Tachycardia 
b. Atrial Fibrillation 
c. Ventricular arrhythmias. 
 42 
2.BONE: 
30 
The prevalence of osteoporosis is high in these patients 
independent of glucocorticoid use. Inflammatory mediators such as 
TNF-α and IL-1 stimulates mesenchymal cells to release receptor 
activator of NFКB ligand which mediates macrophage transformation 
to osteoclasts & accelerates osteoporosis. Other factors such as old 
age, decreased BMI, smoking and sedentary life style may contribute. 
3. DIABETES MELLITUS: 
30 
Undoubtedly there is an increased prevalence of T2DM in these 
patients due to systemic inflammation which is strenghthened by the  
finding of elevated levels of inflammatory markers such as tumour 
necrosis factor α, interleukin 6 & C-reactive protein which further 
compounds the risk of developing CVD. 
4.  MUSCULOSKELETAL SYSTEM : 
27,30 
Progressive muscle wasting with preserved fat mass is a feature 
of the disease. 
Mechanism 
 Increased IL-6 
 Decreased diet intake 
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 Endocrine abnormalities 
i. Decreased Insulin like Growth Factor-1 expression and its 
binding proteins 
ii. Decreased testosterone 
iii. GH resistance 
 Hypoxia 
Muscle dysfunction-respiratory and non-respiratory muscles 
adversely affect the exercise tolerance & health status of the patient & 
the loss of skeletal muscle is an important negative predictive factor 
for survival in these patients and also the BODE index – validated 
index incorporates BMI as one of its four parameters predicting 
prognosis of the disease. 
5. DEPRESSION : 
30 
Increased prevalence due to  
i. Systemic inflammation 
ii. Dependence due to increasing disability 
iii. Impaired Quality of Life 
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NEED FOR IDENTIFYING CONSEQUENCES:
 30 
A knowledge of the systemic consequences enlightens us the 
need for investigating these patients for the comorbidities and to 
intervene early so as to decrease the morbidity and mortality and 
improving the QOL and also to look for the disease in patients 
presenting with any of these co-morbidities. 
C-REACTIVE PROTEIN 
It is an acute phase reactant produced by the hepatocytes and to 
some extent by vascular endothelial and smooth muscle cells in 
response to inflammatory mediators released by macrophages and 
adipocytes. It belongs to the pentraxin family of proteins. The name is 
derived from its finding as an agent in patients with inflammation that 
reacted with the C-polysaccharide of Streptococcus pneumoniae. The 
gene encoding is on chromosome 1q21-q23. 
16,41 
FUNCTION 
BENEFICIAL EFFECTS  
It binds to phosphocholine exposed on micro organisms and 
damaged cells and enhances their removal by phagocytosis by 
macrophages (opsonisation). It is also a part of innate immunity.
 14,16 
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NEGATIVE EFFECTS 
CRP is a pro-inflammatory agent. It directly activates the 
complement cascade by binding to C1q causing tissue destruction. It 
also enhances NFКB to induce the synthesis of various cytokines 
perpetuating inflammation which when unchecked results in 
extensive host tissue damage.
16 
CLINICAL IMPLICATIONS 
CRP is increased in acute and chronic inflammation, auto 
immune diseases, malignancy, and conditions associated with tissue 
damage.
13
 It is a more sensitive and more accurate marker of acute 
inflammation than ESR. The degree of increase correlates with the 
severity of inflammation. It returns to normal with subsidence of 
inflammation rapidly with a t1/2 of 18 hrs and hence can be used to 
monitor response to treatment.     
Value of Highly Sensitive C-Reactive protein above 3 mg/L is 
considered abnormal. 
41 
Highly sensitive methods for assaying CRP known as hs-CRP 
was developed to enhance the sensitivity of detecting the low grade 
inflammation in disease process such as atherosclerosis which routine 
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assays could not detect. Highly Sensitive C-Reactive protein is a 
predictor of CVA, sudden cardiac death, CAD and peripheral vascular 
diseases.
13
 It is a prognostic indicator and mortality predictor in acute 
coronary syndrome. 
41 
Highly Sensitive C-Reactive protein in COPD: 
MECHANISM OF ELEVATION 
Interleukin 6 is the important molecule that upregulates the 
hepatic production of C-Reactive Protein. 
15,16,17 
SOURCE OF INCREASED INTERLEUKIN 6 : 
i. Interleukin 6 may be released by the activated inflammatory cells – 
macrophages in the pulmonary circulation and alveolar epithelial 
cells. 
14
 
ii. Oxidant stress induced derangement in muscle metabolism 
homeostasis causing enhanced expression of  interleukin 6. 
40
 
The increased plasma levels of IL-6 stimulates the hepatocytes to 
express C-Reactive Protein. 
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CLINICAL IMPLICATIONS 
Highly Sensitive C-Reactive protein 
i. Is increased even in stable patients 16,17,18 
ii. Predictor of mortality 14,18,40 
iii. Increased significantly in patients with low body mass index than 
others signifying malnutrition 
iv. Marker of low grade systemic inflammation in these patients 13,16,18,40 
v. Marker of increasing severity of the disease  
vi. Predicts exacerbations, hospitalization 14,18 
vii. Negative correlation with decline in lung function 12,16,18,21,24,28,40 
viii. Elevated levels are associated with poor quality of life & reduced 
exercise tolerance.
 14,18
 
SMOKING CESSATION 
4,30 
Smoking cessation is by far the best effective intervention in 
halting the disease process. 
Approach  
a. Counseling 
b. Pharmacological assistance 
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CONSELLING 
Counseling either by the clinician or non clinician enhances 
cessation rate several fold than self initiated attempts. 
5A intervention approach 
I. ASK – information about tobacco use at every visit. 
II. ADVICE – should be strong and individualized depending on 
patient’s health status and other considerations. 
III. ASSESS – patient’s willingness. If patient is not willing he/she 
should be urged to quit. 
IV. ASSIST – by discussing with the patient a quit plan; setting a date to 
stop smoking in next 2 weeks, to reduce alcohol use, educate 
households and providing psycho social support. 
V. ARRANGE – follow-up. 
PHARMACOTHERAPY 
4,6,30 
First line agents 
Nicotine Replacement Therapy 
Formulations available 
Gum 
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Dose   : 2 mg – 1-24 cigarettes/d ; 4 mg - >25 cigarettes/d 
Duration  : 12 weeks 
Adverse effects : dyspepsia 
Lozenge 
Dose : 2 mg – first smoke > 30 min after waking up from bed; 4 mg – 
first smoke < 30 min after waking up from bed 
Maximum of 20 mg/d 
Duration  :  12 weeks 
Side effects :  nausea, insomnia. 
Inhaler 
Dose   : 6 – 16 cartridges of 4 mg each/d 
Duration  : 6 months with dose reduction in last 3 months 
Side effects  : rhinitis, local irritation 
Spray 
Dose   :  0.5 mg in each nostril 1-2 doses/hr 
Maximum 5/hr 
Duration  :  3-6 months 
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Side effects : local irritation 
Patch 
Dose : 16 or 24 hr patch for total duration of 8 weeks with dose 
reduction 
Side effects  : local skin reaction, insomnia 
Advantage   : good compliance, requires less skill. 
Contra indication to NRT : 
 Coronary artery disease – MI or unstable angina 
 Cerebrovascular accident 
 Untreated Acid peptic disease 
Bupropion sustained release 
Mechanism of action 
Nor-epinephrine and dopamine reuptake inhibitor 
Dose : 150 mg once daily x 3 days; 150 mg bd x 7- 12 weeks 
Duration : 6 -12 months 
Side effects : insomnia, dry mouth 
Contra indications : epilepsy, MAOI use in past 2 weeks 
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Particularly preferred in patients with concomitant depression 
Varnecline 
Mechanism of action  
Partial agonist of nicotinic Ach receptor 
Dose : 0.5 mg od x 1-3 days; 0.5 mg bd x 4-7 days; 1 mg bd from 
then up to 8 weeks. 
Side effects : CNS – suicidal intention which has resulted in FDA 
warning. 
Second line agents 
1. Clonidine :  
Mechanism of action : post synaptic α2 agonist 
Dose : 0.1 – 0.4 mg/d x 2 -6 weeks 
2. Anxiolytics 
Diazepam, buspirone, beta blockers 
3. Sensory replacement 
Citric acid inhaler, denicotinised tobacco, black pepper extract 
4. Acupuncture : by releasing endorphins 
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Antagonists 
a. Mecamylamine  
non competitive CNS and PNS nicotine receptor antagonist 
b. Naltrexone. 
Aversion causing drugs 
Silver acetate – poor compliance 
SMOKING PREVENTION 
4,30 
Smoking behavior in around 90% smokers were initiated during 
adolescence. So prevention is more important and effective than 
cessation after the behavior has begun. 
Measures : 
1. Health education – target population : adolescents, young adults 
2. Public health programs 
3. Smoke free public places.  
EMERGING THERAPIES  
 Newer drugs have been developed with the aim of inhibiting 
one of the several steps involved in the inflammatory pathogenesis of 
COPD with the concern of developing effective but also safe drugs. 
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Oxidative stress – imbalance between pulmonary oxidant load 
and anti-oxidants causing inflammation and airway modeling – an 
important pathogenetic mechanism – probably the reason for steroid 
resistance has been the target for newer therapies. 
30 
SMOKING CESSATION 
An important and effective intervention to arrest the decline of 
lung function is smoking cessation. 
Recent research has developed anti-free nicotine antibodies 
which bind with free nicotine denying its access across the BBB and 
hence cannot stimulate nicotine receptors causing smoking an 
unpleasant experience.  
30 
NEWER BRONCHODILATORS 
Bronchodilators though they do not arrest the disease process – 
provide immediate symptom relief  and improves well being of the 
patient are an important component of treatment plan. 
Newer long & ultra long acting bronchodilators have been 
developed to meet the short comings of short acting ones – poor 
compliance due to multiple dosing. These include ultra-long acting 
muscarinic antagonists and ultra-long acting β2 agonists. 30 
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ULTRA-LONG ACTING MUSCARINIC ANTAGONISTS 
These agents besides providing long acting bronchodilatation 
have been shown to decrease the number of exacerbations and so they 
have the ability to attenuate the disease process partially and hence 
provide mortality benefit. 
30 
Drugs under research: 
i. Aclidinium 
ii. Dexpironium 
iii. TD-4208 
iv. Daratropium bromide 
v. GSK-573719 
vi. Glycopyronium bromide 
ULTRA-LONG ACTING β2 AGONISTS 30 
This includes 
i. Indacaterol – approved in Europe & USA 
ii. Vilanterol – safe & efficacious 
iii. Carmoterol – using modulate technology, the amount of inhaled 
drug reaching the target has been increased 
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iv. Milveterol – proved efficacious in asthma, not yet researched on 
COPD 
v. GSK-642444 
vi. UK-503590 
vii. BI-1744-CL 
viii. Compound X 
NOVEL COMBINATIONS 
 Rationale of combing long acting drugs 
a) Synergism between the two agents 
b) Patients based on whether beta or muscarinic receptor predominance 
in their airway respond to their respective drugs more than the other 
and hence their combination can overcome their problem of receptor 
variation. 
Several combination of these agents along with steroids to 
decrease exacerbations are under development but a potential 
limitation of using these combination is delivery of  these agents at 
different site which decrease their synergism. To overcome these 
limitation combining them into a dimer which serves to deliver the 
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agents at same site – dual acting muscarinic antagonist beta 2 agonist 
have emerged. 
Other combinations under development are combining a LABA 
with an ICS or combining LABA with inhaled steroid and LAMA. 
30 
ANTI INFLAMMATORY DRUGS 
The search for an effective and safe anti inflammatory drug 
with the potential of reducing lung inflammation over the decades 
have been in vain. One of the recent break through finding is that 
oxidative stress causing decrease in HDAC in these patients has been 
the reason for corticosteroid unresponsiveness in them and that this 
enzyme at cellular levels can be increased by theophylline. Hence 
theophylline has staged a comeback in management of the disease 
with the potential of additive anti-inflammatory effect when given 
with steroids and studies are underway on this aspect. 
30 
PDE-4 INHIBITORS 
30 
Phosphodiesterase-4 an enzyme found specifically in most 
inflammatory cells have been targeted to reduce the inflammatory 
process of the disease. Roflumilast selective PDE-4 inhibitor has been 
approved for use. It has shown to increase FEV1 significantly than 
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tiotropium. These drugs could be the best adjuvant therapy with 
bronchodilators. An inhalational form of this class is under study. But 
the side effects of this drug – gastrointestinal and upper respiratory 
tract effects have led to search for development for specific inhibitors. 
ANTI PROTEASES
 30 
An imbalance between proteases (matrix metallo proteinases) – 
anti proteases is an important pathogenetic mechanism of 
emphysema. Anti proteases – MMP inhibitors have shown promising 
results in preventing emphysema. Few drugs of this class are under 
phase II and III trials. 
1. Marimastat – non selective MMP inhibitor 
2. AZ11557272 – dual MMP-9/MMP-12 inhibitor 
CYTOKINE INHIBITORS 
30 
Tumour necrosis factor – α and other interleukins – notably IL-
7, IL-1β, IL-6 are important cytokines implicated in the systemic 
inflammatory process in the disease. Drugs targeting these cytokines 
are in the infant phase. 
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CHEMOKINE ANTAGONISTS 
30 
Oral AD28309 – CXCR1/2 receptor antagonist – the receptor 
which mediates the effects of chemokines on inflammatory cells has 
shown to reduce inflammation in man. Other receptors targeted are 
CXCR 3 and 5 and drugs involved in these have finished phase I 
trials. 
TGF-β INHIBITORS 30 
SD-280 which inhibits the fibrogenic cytokine TGF-β causing 
small airway fibrosis resulting in decrease in FEV1 and reduced 
exercise capacity has been developed but the long term consequences 
of this class are yet unknown. 
NFКB INHIBITORS 30 
Inhibition of NFКB – a transcription factor involved in 
upregulating the production of various chemokines, TNF-α and 
MMP-9 seems to be a potential option. Such inhibitors are presently 
under research. 
P38MAPKinase INHIBITORS : 
30
  
Inhaled formulation of inhibitors of this enzyme which 
upregulates the production of interleukin 8, TNF α and few other 
mediators causing inflammation are now in development period. 
 59 
PHOSPHOINOSITOL-3-KINASE INHIBITORS under research. 
30 
PPAR AGONISTS 
30 
Immunomodulatory effects of PPAR α and γ (also inhibits 
TGF-β ) are being exploited and the drugs currently being studied are 
rosiglitazone and SB-219994. 
ANTIOXIDANTS 
30 
Anti oxidant drugs being used are 
I. NAC and its derivatives 
a. N-Acetyl Cysteine 
i. Decreases systemic and pulmonary oxidative stress 
ii. Mild bronchodilation 
iii. Halts decrease in FEV1 
iv. Reduces exacerbation 
b. N-acestelyn – well tolerated 
c. Erdosteine – added advantage of reducing bacterial adhesion 
thereby reducing  exacerbations. 
d. Carbocysteine 
e. Procysteine – toxic 
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f. N – isobutyryl cysteine – less effective 
II. NRF-2 Activators 
STATINS 
30 
The pleomorphic action of statins apart from lipid lowering 
such as anti-oxidant, endothelial protection and anti inflammatory 
properties in retrospective analysis have shown to decrease mortality, 
reduce exacerbations, decreasing need for assisted ventilation, 
improving functional capacity and reduce FEV1 decline. But 
randomized controlled trials are required to confirm their 
effectiveness before being part of management plan of the disease. 
REGENERATIVE THERAPIES 
Currently research is focusing on a modality of treatment that 
could actually bring back the destroyed lung tissue and hence 
restoring the normal anatomy which in future if discovered can 
revolutionize the COPD management. 
30 
STEM CELLS 
Allogenic mesenchymal stem cells have the prospect of 
restoring alveolar tissue but clogging of pulmonary vasculature with 
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these cells resulting in death is an undesirable outcome. Trials are 
currently under research to overcome this side effect. 
30
  
RETINOIC ACID 
ATRA can cause regeneration of distal respiratory unit and 
hence reverse emphysema but in clinical trials have not shown such 
benefits.
 30 
ANTI-AGEING THERAPY 
Oxidative stress causing accelerated ageing by increasing DNA 
damage mediated by inactivation by SIRT1 or SIR2 protein1 being 
focused as a target for arresting the disease process. 
30 
Besides these discoveries,  research are also on to find a better 
way of enhancing the amount of drugs delivered to the desired 
segment of lung by using either new carrier formulation, 
nanotechnology, liposomal formulations or agents to enhance 
absorption such as surfactant, hyaluronic acid, taurocholate,etc. 
Several hundreds or thousands of newer treatment 
modalities/drugs may emerge but still the best and most effective 
intervention is cessation of smoking. 
30 
 
 62 
MATERIALS AND METHODS 
DESIGN OF STUDY  :  Cross sectional study 
PERIOD OF STUDY   :  April 2012 – October 2012 
SELECTION OF STUDY SUBJECTS : Outpatients attending the 
medical and thoracic medicine department 
STUDY POPULATION  :  70 cases 
ETHICAL CLEARANCE  :  Obtained 
CONSENT    :  Informed consent obtained 
CONFLICT OF INTEREST  :  Nil 
FINANCIAL SUPPORT  :  Nil. 
INCLUSION CRITERIA 
Patients attending the out patient department with symptoms 
suggestive of chronic obstructive pulmonary diseases ( chronic cough 
with sputum , shortness of breath, wheeze ) who were clinically stable 
were subjected to PFT and whose FEV1/FVC < 0.70 (GOLD 
guidelines) were chosen. 
EXCLUSION CRITERIA 
a. PFT showing features of bronchial asthma ( post bronchodilator 
reversibility > 15% baseline value ) 
b. Patients in acute exacerbations or clinically unstable 
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c. Pulmonary tuberculosis 
d. Diabetes mellitus 
e. Ischaemic heart disease 
f. Cerebrovascular accident 
g. Any acute infection or inflammation ( rheumatoid arthritis, 
autoimmune diseases ) 
h. Malignancy  
i. Hepatic or renal impairment 
STUDY 
70 cases were selected for the study after applying the inclusion 
and exclusion criteria as stated above and subjected to the following 
Baseline data and clinical characteristics 
The baseline characteristics of the patients – age, sex, 
occupation, smoking habit and the clinical characteristics – symptoms 
and signs by thorough examination were recorded in the proforma 
prepared according to the need of study. 
Spirometry 
Pulmonary function test was done using the spirometer machine 
in the department of thoracic medicine after properly instructing the 
patient and post bronchodilator values after 20 min of salbutamol 
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nebulisation were recorded and the test was repeated twice and the 
best of the two was taken and based on FEV1 % predicted value 
patients were classified into stages based on GOLD guidelines. 
 
Other investigations 
 Height, weight were recorded and BMI calculated. 
 X-ray chest Postero-anterior view was taken for all patients and the 
nature of COPD was ascertained 
 ECG was taken and analysed for signs of pulmonary hypertension, 
cor pulmonale or coronary artery disease. 
 Echocardiography was done in the department of cardiology to assess 
for the presence of pulmonary hypertension, its severity and right 
heart enlargement/dysfunction 
 Blood investigations – basic blood investigations, ESR and serum 
albumin were done. hs-CRP was assayed by nephalometric method. 
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OBSERVATION AND RESULTS 
A total of 70 cases were studied. Data collected from the 
patients were entered in Microsoft excel 2007 spread sheet and 
analysed with simple statistical analysis. 
TABLE – 1 
STAGES OF COPD 
STAGE NO.OF 
CASES 
PERCENTAGE MEAN 
FEV1% PV 
S.D 
I 8 11.4 84.00 2.39 
II 33 47.1 67.94 6.89 
III 24 34.3 42.21 4.19 
IV 5 7.2 28.20 1.48 
TOTAL 70 100   
 
Of the 70 patients, 8 patients (11.4%) were in stage I, 
33(47.1%) were in stage II, 24(34.3%) were in stage III and 5(7.2%) 
were in stage IV during the period of study. The mean FEV1% of 
predicted value of each stage is also shown in the table.(fig 1) 
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TABLE – 2 
AGE DISTRIBUTION 
 
 21-30 31-40 41-50 51-60 61-70 71-80 TOTAL 
I 1 5 - 2 - - 8 
II 3 9 10 11 - - 33 
III - 1 6 7 7 3 24 
IV - - - - 1 4 5 
TOTAL 4 15 16 20 8 7 70 
% 5.7 21.4 22.9 28.6 11.4 10 100 
 
The maximum number of patients belonged to the 51-60 age 
group (28.6%) and 21-30 age group (5.7%) constituted the 
minimum.(fig 2) 
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TABLE – 3 
AGE DISTRIBUTION ACCORDING TO STAGE 
AGE MEAN S.D 
I 39.25 10.58 
II 44.91 9.17 
III 57.21 10.13 
IV 73.20 4.21 
p   < 0.001  Significant 
 
TABLE – 4 
AGE  WITH FEV1 % OF PREDICTED VALUE 
FEV1 % PV p VALUE 
AGE 0.004 Significant 
 
The increase in age with the increasing stage of the disease was 
found to be statistically significant with p < 0.001 and the correlation 
of age with FEV1% of predicted value was also found to be 
statistically significant.(fig 3) 
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TABLE – 5 
SEX 
 N MALE % FEMALE % 
I 8 6 8.9 2 66.7 
II 33 32 47.8 1 33.3 
III 24 24 35.8 - - 
IV 5 5 7.5 - - 
TOTAL 70 67 100 3 100 
 
Of the total 70 patients, 67 (95.7%) were males and 3 (4.3%) 
were females.(fig 4) 
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TABLE - 6 
OCCUPATION 
OCCUPATION N % 
MANUAL LABOURERS 53 75.8 
COTTON INDUSTRY 5 7.1 
FLOUR MILL 6 8.6 
BUSINESS 4 5.7 
PROFESSIONAL 1 1.4 
DYE INDUSTRY 1 1.4 
TOTAL 70 100 
 
Of the total 70 patients, 53(75.8%)were manual labourers, 
6(8.6%) were working in flour mill, 5(7.1%) in cotton industry, 
4(5.7%) were in business,1 (1.4%) in dye industry and 1(1.4%) was a 
professional.(fig 5) 
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TABLE – 7 
SYMPTOMS 
SYMPTOMS N % 
Chronic cough 70 100 
Sputum production 70 100 
Shortness of breath 62 88.6 
Wheeze  51 72.9 
 
All the patients had chronic cough with sputum production, 
88.6% had shortness of breath and 72.9% gave a history of 
wheeze.(fig 6) 
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TABLE - 8 
SIGNS 
SIGNS N % 
Elevated JVP 15 21.4 
Pedal edema 11 15.7 
Diminished air entry 31 44.3 
Wheeze 47 67.1 
Crackles 39 55.7 
Downward liver 
displacement 
24 34.3 
 
Of the 70 patients, 15(21.4%) had elevated JVP, 11(15.7%) had 
pedal edema, 31(44.3%) diminished air entry, 47(67.1%) wheeze, 
39(55.7%) crackles on auscultation and 24(34.3%) had downward 
displacement of liver due to air trapping and hyperinflation.(fig 7) 
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TABLE - 9 
X-RAY CHEST PA VIEW 
Stage N Normal % CB % E % CB + E % 
I 8 8 100 - - - - - - 
II 33 5 15.2 10 30.3 10 30.3 8 24.2 
III 24 - - 6 25 10 41.7 8 33.3 
IV 5 - - 1 20 1 20 3 60 
 
Of the 70 patients, 13 patients had normal X-ray, 17 patients 
had features of chronic bronchitis, 21 had findings suggestive of 
emphysema and 19 patients showed features of both chronic 
bronchitis and emphysema.(fig 8) 
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TABLE - 10 
ELECTROCARDIOGRAM 
 I II III IV TOTAL 
RAE - 1 6 5 12 
RVH - 2 5 3 10 
Right axis deviation - 1 2 3 6 
Right Bundle Branch Block 1 3 4 2 9 
Lead I sign - 9 8 3 20 
PPRW - 6 9 2 17 
 
Among patients with stage I disease (8) 1 patient had ECG 
criteria for right bundle branch block, stage II disease(33) 1 patient 
showed features of right atrial enlargement ( p wave > 2.5mm), 2 
patients had right ventricular hypertrophy ( R in V1 > 7mm or R/S in 
V1>1), 1 had right axis deviation,3 showed right bundle branch block, 
9 had lead I sign ( small equiphasic QRS complex in lead I – due to 
hyperinflation of lungs and rotation of heart ) and 6 had poor R wave 
progression. Among patients with stage III disease, 6 showed RAE, 5 
RVH, 2 right axis deviation, 4 right bundle branch block, 8 lead I sign 
and 9 poor progression of R wave. In stage IV disease 5 had right 
atrial enlargement,3 right ventricular hypertrophy, 3 had right axis 
deviation,2 RBBB,3 lead I sign and 2 had poor R wave 
progression.(fig 9) 
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TABLE - 11 
ECHOCARDIOGRAPHY 
Stage N Mild % Moderate % Severe % RV 
dilatation 
% 
I 8 - - - - - - - - 
II 33 3 42.9 1 10 - - - - 
III 24 4 57.1 5 50 2 66.7 2 33.
3 
IV 5 - - 4 40 1 33.3 4 66.
7 
TOT
AL 
70 7 100 10 100 3 100 6 100 
 
Of the total 70 patients, 7 patients – 3 in stage II and 4 in stage 
III had mild pulmonary hypertension, 10 patients – 1 in stage II, 5 in 
stage III and 4 in stage IV had moderate pulmonary hypertension, 3 
patients – 2 in stage III and 1 in stage IV had severe pulmonary 
hypertension. Of the 6 patients with RV enlargement 2 were in stage 
III and 4 in stage IV.(fig 10) 
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TABLE –12 
BODY MASS INDEX WITH STAGE 
BODY MASS INDEX MEAN S.D 
I 26.43 4.16 
II 23.91 1.84 
III 21.50 2.07 
IV 18.78 1.98 
p < 0.001  Significant 
 
The body mass index showed a decreasing trend with increasing 
stage of the disease and the association was found to be statistically 
significant. ( p < 0.001 ) (fig 11) 
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TABLE – 13 
PACK YEARS OF SMOKING WITH STAGE 
PACK YEARS OF 
SMOKING 
MEAN S.D 
I 13.75 9.91 
II 30.61 10.81 
III 41.25 6.29 
IV 52.00 4.47 
p   < 0.001  Significant 
 
TABLE – 14 
FEV1% OF PREDICTED VALUE WITH PACK YEARS 
FEV1% OF PV P 
PACK YEARS OF SMOKING < 0.001 Significant 
 
The study showed that there is an increase in severity of the 
disease as depicted by GOLD stage with the increase in the number of 
pack years of smoking and it was statistically significant (p < 0.001). 
Also the decline in FEV1 % of predicted value also showed a 
significant association with the number of pack years of smoking.(fig 
12) 
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TABLE – 15 
ERYTHROCYTE SEDIMENTATION RATE WITH STAGE 
ERYTHROCYTE 
SEDIMENTATION RATE 
Mean S.D 
I 22.13 11.13 
II 23.18 8.37 
III 26.04 6.28 
IV 36.00 11.23 
p = 0.012  Significant 
 
TABLE – 16 
FEV1% OF PREDICTED VALUE WITH ERYTHROCYTE 
SEDIMENTATION RATE 
FEV1% OF PV P 
ERYTHROCYTE 
SEDIMENTATION RATE 
< 0.001 Significant 
 
The mean erythrocyte sedimentation rate in each stage were 
tested for significance and was found to be statistically significant 
with p value = 0.012. Similarly the correlation between erythrocyte 
sedimentation rate and FEV1% of predicted value was also found to 
be significant.(fig 13) 
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TABLE – 17 
SERUM ALBUMIN WITH STAGE 
SR. ALBUMIN MEAN S.D 
I 4.43 0.35 
II 3.91 0.36 
III 3.62 0.35 
IV 2.56 0.39 
p   < 0.001  Significant 
 
TABLE – 18 
FEV1% OF PREDICTED VALUE WITH SERUM ALBUMIN 
FEV1% OF PV P 
SERUM ALBUMIN < 0.001 Significant 
 
Serum albumin concentration was found to decrease among 
patients with increasing disease severity and the decrease was found 
to be statistically significant (p < 0.001 ). Also with declining FEV1% 
of predicted value serum albumin was found to significantly decrease. 
( p < 0.001)  (fig 14) 
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TABLE – 19 
HIGHLY SENSITIVE CRP WITH STAGE 
HIGHLY 
SENSITIVE CRP 
MEAN S.D 
I 3.91 1.26 
II 5.79 1.23 
III 9.01 0.96 
IV 11.98 0.73 
p  < 0.001  Significant 
 
TABLE – 20 
HIGHLY SENSITIVE CRP 
 I II III IV ‘p’ value 
≤ 3 mg/L   
 (3) 
2 1 0 0 0.421 Not 
Significant 
>3 mg/L   
(67) 
6 32 24 5 < 0.001 
Significant 
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TABLE – 21 
FEV1% OF PREDICTED VALUE WITH HIGHLY  
SENSITIVE CRP 
FEV1% OF PV P 
HIGHLY SENSITIVE CRP < 0.001 Significant 
 
Among the 4 stages, the concentration of highly sensitive C-
Reactive Protein was highest in stage IV disease and the increase in 
highly sensitive C-Reactive Protein with disease severity was found 
to be statistically significant with  p < 0.001.(fig 15). Also among the 
total 70 patients, 67 patients had increased highly sensitive C-
Reactive Protein of  > 3 mg/L and only 3 patients had normal values. 
When statistically tested between the normal vs abnormal groups 
among the stages it was found to significant.(fig 16). Similarly, the 
correlation between FEV1% of predicted value with this marker of 
inflammation was also statistically significant ( p < 0.001). 
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DISCUSSION 
COPD is one of the several diseases whose morbidity and 
mortality is increasing day by day at an alarming rate and imposing 
economic burden on the nation.
34
 Despite advances in diagnosis and 
management the disease still remains untamed. The disease has been 
recognized as one with systemic manifestations and several markers 
are being tested everyday to possibly reflect the entire disease 
process, but the ‘ideal’ marker still remains an enigma. In our study, a 
total of 70 patients were studied after applying the inclusion and 
exclusion criteria; their clinical status analysed and markers of 
inflammation were correlated with severity to determine their 
significance.  
AGE 
In our study, the increase in age with the increasing stage of the 
disease was found to be statistically significant with p < 0.001 and the 
correlation of age with FEV1% of predicted value was also found to 
be statistically significant.  The risk of developing the disease has 
been shown to increase with age.
43
 This may due to the age related 
deterioration of lung function or increase in duration of smoking or 
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sustained exposure to environmental risk factors or a combination of 
any these, one compounding the effects of the other. 
SEX 
Of the total 70 patients, 67 (95.7%) were males and 3 (4.3%) 
were females. This is because smoking, the important risk factor is 
common in males. 
4 
SMOKING 
The study showed that there is an increase in severity of the 
disease as depicted by GOLD stage with the increase in the number of 
pack years of smoking and it was statistically significant. Also the 
decline in FEV1 % of predicted value also showed a negative 
correlation with the number of pack years of smoking which is 
consistent with other studies. Smoking in any form has been regarded 
as the most important risk factor in almost every study for developing 
the disease and has been proven to have a dose – response 
relationship.
 4,5,6
 On reviewing several studies on Indian male patients, 
82.3% were associated with smoking.
39 
 
 
 98 
OCCUPATION 
Of the total 70 patients, 53(75.8%) were manual labourers, 
6(8.6%) were working in flour mill, 5(7.1%) in cotton industry, 
4(5.7%) were in business,1 (1.4%) in dye industry and 1(1.4%) was a 
professional. Several occupation which are associated with chemicals, 
noxious gases, minerals, dust, cotton industry have been identified as 
risk factors and the risk is further compounded if smoking is also 
present.  
30 
SYMPTOMS 
In our study, all the patients had chronic cough with sputum 
production and a majority had shortness of breath and wheeze – the 
cardinal symptoms of the disease. 
SIGNS 
Of the 70 patients, 15 had raised JVP, 11 had pedal edema 
which could be due to hypoalbuminemia or cor pulmonale, 31 
diminished air entry, 47 wheeze, 39 crackles on auscultation and 24 
had downward displacement of liver due to air trapping and 
hyperinflation. 
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X-RAY CHEST PA VIEW 
Among the 70 patients, 13 patients had normal X-ray, 17 
patients had features of chronic bronchitis, 21 had findings suggestive 
of emphysema and 19 patients showed features of both chronic 
bronchitis and emphysema. These inferences show that imaging could 
not be used to diagnose the disease particularly in its early stages
 
 and 
also that the two forms of the disease is not mutually exclusive as 
patients over time may develop features of the two. 
10 
ELECTROCARDIOGRAM 
Among patients with stage I disease (8) 1 patient had ECG 
criteria for right bundle branch block, stage II disease(33) 1 patient 
showed features of right atrial enlargement, 2 patients had right 
ventricular hypertrophy, 1 had right axis deviation,3 showed right 
bundle branch block, 9 had lead I sign and 6 had poor R wave 
progression. Among patients with stage III disease, 6 showed RAE, 5 
RVH, 2 right axis deviation, 4 right bundle branch block, 8 lead I sign 
and 9 poor progression of R wave. In stage IV disease 5 had right 
atrial enlargement,3 right ventricular hypertrophy, 3 had right axis 
deviation,2 RBBB,3 lead I sign and 2 had poor R wave progression. 
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Several studies have demonstrated the ECG changes including right 
atrial enlargement, right axis deviation, right bundle branch block, 
low voltage complexes in these patients as the disease progresses.
36
 
The criteria for diagnosing right ventricular hypertrophy cannot detect 
all cases in these patients due to cardiac rotation and hyperinflation of 
lungs.
44
 Antonelli incalzi et al showed that SI SII SIII pattern and 
right atrial overload was significantly associated with increased risk 
of death. ECG findings though less sensitive are highly specific. 
22 
ECHOCARDIOGRAPHY 
Of the total 70 patients, 7 patients – 3 in stage II and 4 in stage 
III had mild pulmonary hypertension, 10 patients – 1 in stage II, 5 in 
stage III and 4 in stage IV had moderate pulmonary hypertension, 3 
patients – 2 in stage III and 1 in stage IV had severe pulmonary 
hypertension. Of the 6 patients with RV enlargement 2 were in stage 
III and 4 in stage IV. Various factors – alveolar hypoxia, lung 
hyperinflation, parenchymal destruction altering pulmonary 
hemodynamics culminate in pulmonary hypertension and 
subsequently right ventricular dysfunction in these patients. Right 
ventricular failure if present is an independent marker of poor 
prognosis and is a cause for increase in breathlessness, reduced 
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exercise tolerance and hence their identification is crucial to reduce 
morbidity and mortality and all these patients should be investigated 
for the same by echocardiography and if needed catheterization 
studies. 
23 
BODY MASS INDEX 
In our study, the body mass index showed a decreasing trend 
with increasing stage of the disease and the association was found to 
be statistically significant. (p < 0.001). Unintentional weight loss 
particularly the fat free mass in these patients is termed pulmonary 
cachexia. The cause is multifactorial and has been attributed to a 
combination of systemic inflammation, pulmonary gas exchange 
abnormalities resulting in hypoxia, genetic predisposition, oxidative 
stress and several other factors.
3
 The consequences are muscle 
dysfunction – respiratory increasing dyspnoea and work of breathing 
and non respiratory causing reduced exercise capacity, impaired 
quality of life and is a risk factor for increase in mortality irrespective 
of lung function.
19,26,33
 H.Gunen et al showed that long term risk of 
death increased in patients with body mass index < 20 kg/sq.m.
1
 Body 
mass index is part of the BODE index a validated score used for 
predicting prognosis in these patients.
6 
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ALBUMIN 
Among our patients, serum albumin concentration was found to 
decrease among patients with increasing disease severity as per the 
stage of the disease and the decrease was found to be statistically 
significant. Also serum albumin showed positive correlation with 
declining FEV1% of predicted value. Albumin is a negative acute 
phase reactant,
32
 the concentration of which decreases with 
inflammation and also its concentration decreases with chronic 
debilitating diseases. H.Gunen et al showed that serum albumin < 2.5 
g/dL was associated with long term risk of mortality and thus low 
serum albumin serves as a poor prognostic marker.
1
 Low serum 
albumin has also been shown to be a surrogate marker of other 
inflammatory markers.
2
  
ERYTHROCYTE SEDIMENTATION RATE 
In our study erythrocyte sedimentation rate was found to 
increase with the stage and decrease in FEV1% of predicted value and 
the association was found to be statistically significant. Several 
studies have analysed the usefulness of erythrocyte sedimentation rate 
as a marker of inflammation and disease severity because of its 
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availability and cost. The inferences are conflicting with some 
indicating erythrocyte sedimentation rate increases with disease 
severity
 45
 while others concluded that it could not be used as a marker 
of severity.
2 
 HIGHLY SENSITIVE C-REACTIVE PROTEIN 
Since the recognition of COPD as a systemic inflammatory 
state which contributes much to the morbidity and mortality, 
extensive research have been done to tame the inflammation and 
hence a search for a ‘ideal’ biomarker which could mirror the disease 
process and which could be used for predicting prognosis, monitoring 
treatment  is still on. Of the several biomarkers being added everyday 
to the existing list, highly sensitive C-reactive protein has performed 
fairly consistently across studies and hence we chose it for our study. 
In the present study, among the 4 stages, the concentration of highly 
sensitive C-Reactive Protein was highest in stage IV disease and the 
increase in highly sensitive C-Reactive Protein with disease severity 
was found to be statistically significant with  p < 0.001. Also among 
the total 70 patients, 67 patients had increased highly sensitive C-
Reactive Protein of  > 3 mg/L and only 3 patients had normal values. 
When statistically tested between the normal vs abnormal groups 
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among the stages it was found to significant. Similarly, the correlation 
between FEV1% of predicted value with this marker of inflammation 
was also statistically significant  which was consistent with the results 
of other studies.
18
 Highly sensitive C-Reactive Protein is a marker of 
disease severity, patients health status and has shown to be raised in 
patients who are stable thus qualifying as a better biomarker.
16,17,18
 
Patients with elevated levels of this marker at baseline have an 
increased risk of hospitalization and mortality as shown by 
studies.
14,18
  In our study, the marker has performed in consistent with 
similar other studies correlating with the disease severity. 
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LIMITATIONS OF THE STUDY 
The study has its own limitations 
 The number of patients involved in the study ‘N’ is small and 
hence generalization of the results of the study have to be made 
with caution. 
 The study population involved only the patients seeking 
medical care in our hospital which is a tertiary care centre and 
hence they may not represent the general population. 
 This study is a cross sectional study and hence it represents the 
characteristics and variables tested in the study population at 
that point of time. Longitudinal studies with serial assessment 
of the variables would be more informative. 
So, longitudinal studies with large study population and population 
based studies are needed to circumvent these limitations.  
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CONCLUSIONS 
From our study we conclude that 
 Increasing age is associated with severity of the disease. 
 Males are more commonly affected than females because of 
smoking. 
 Occupational exposure to risk factors compounds the risk of 
developing the disease when associated with smoking. 
 Incidence of pulmonary hypertension and right ventricular 
dilatation increases with increasing severity of the disease. 
 Body mass index decreases with increasing severity and is a 
poor prognostic marker. 
 The markers of inflammation – Erythrocyte sedimentation rate, 
albumin, Highly Reactive C-Reactive Protein correlates with 
increasing disease severity as evidenced by decreasing FEV1% 
of predicted value and increasing GOLD stage. 
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PROFORMA 
Name :       Patient number : 
Age :        Sex : 
Occupation : 
Address : 
Present History 
Chronic cough 
Sputum 
Shortness of breath 
Wheeze 
Hemoptysis 
Fever 
Other relevant history 
Past history 
History regarding Diabetes, Hypertension, Tuberculosis, Ischemic 
heart disease, CVA or any other chronic diseases. Any chronic drug 
intake. 
Personal history 
Tobacco use – form of use. 
Smoking – duration, pack years of smoking. 
Alcohol intake – duration 
Any history of pre / extra – marital contact. 
Occupation  
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General examination 
Nutrition                Pallor               Icterus               Cyanosis  
Clubbing               Lymphadenopathy                     Pedal edema               
JVP  
Pulse rate              BP                                              Respiratory rate  
Height                  Weight                                        Body Mass Index 
Systemic examination 
Respiratory System 
Air entry                  Breath sounds            Wheeze              Crackles  
CVS  
Abdomen  
CNS 
Investigations  
Hb          TC       DC      ESR              Urine Albumin  Sugar  Deposits  
Blood    Sugar    Urea   Serum Creatinine                     Serum Albumin  
ECG                   X-ray chest PA view                            Echo  
hs-CRP  
HIV 
PFT 
FEV1            FVC          FEV1/FVC            FEV1% of predicted value  
GOLD STAGE 
Diagnosis  
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ABBREVIATIONS 
 
COPD  –  Chronic Obstructive Pulmonary Disease 
GOLD  –  Global initiative for chronic Obstructive Lung Diseases 
DALY  –  Disability Adjusted Life Years 
hs-CRP  –  Highly Sensitive C-Reactive Protein 
ECG   -  ElectroCardioGram 
ESR   –  Erythrocyte Sedimentation Rate 
BMI   –  Body Mass Index 
FEV1  –  Forced Expiratory Volume in 1 second 
FVC   –  Forced Vital Capacity 
ICMR  –  Indian Council of Medical Research 
HCHO -  formaldehyde 
AT   –  Anti -Trypsin 
RV   –  Residual Volume 
TLC   –  Total Lung Capacity 
FRC   –  Functional Residual Capacity 
ROS   –  Reactive Oxygen Species  
MMP  –  Matrix Metallo proteinase 
PTE   –  Pulmonary Thrombo Embolism 
ABG   –  Arterial Blood Gas 
PHT   –  Pulmonary HyperTension 
MAT   –  Multifocal Atrial Tachycardia 
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CAD   –  Coronary Artery Disease 
NIV   –  Non Invasive Ventilation 
LTOT  –  Long Term Oxygen Therapy 
TNF α  –  Tumour Necrosis Factor α 
TGF β  –  Transforming Growth Factor β 
IL   -  InterLeukin 
PPAR  –  Peroxisome Proliferator-Activated Receptors 
NFКB  –  Nuclear Factor К B 
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KEY TO MASTER CHART 
M  –  Male 
F  –   Female 
L  -   Manual Labourer 
FM  –  Flour Mill 
CM  –  Cotton Industry 
B  –  Business 
P  –  Professional 
P/ +  –  Present 
A/-  –  Absent 
D  –  Decreased 
N  –  Normal 
R  –  Right  
L  –  Left 
NW  -  North West 
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MASTER CHART 
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1 Rengasamy 27 M L P P A A A A N A A A A A A N A A A A 
2 Anthonysamy 32 M L P P A A A A N P A A A A A N A A A A 
3 Palpandi 34 M L P P P A A A N P A A A A A R A A A A 
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